Filed by the Registrant ☒

Filed by a Party other than the Registrant  ☐

Check the appropriate box:

Payment of Filing Fee (Check all boxes that apply):

 

To our Stockholders:

You are cordially invited to attend the 2026 Annual Meeting of Stockholders and any adjournments or postponements thereof (the “2026 Annual Meeting” or the “Annual Meeting”) of GRACE THERAPEUTICS, INC., a Delaware corporation (the “Company”). The Annual Meeting will be held virtually on September 17, 2026, at 8:30 a.m. Eastern Time at www.virtualshareholdermeeting.com/GRCE2026. You will not be able to attend the Annual Meeting in person. The Annual Meeting will be held for the following purposes:

Our Board recommends that stockholders vote: FOR ALL for Proposal No. 1; FOR Proposals No. 2 and No. 3; and 1 YEAR for Proposal No. 4;

These items of business are more fully described in the Proxy Statement.

The Annual Meeting will be held virtually through a live webcast. You will be able to attend the Annual Meeting, submit questions and vote during the live webcast by visiting www.virtualshareholdermeeting.com/GRCE2026 and entering the 16-digit Control Number included in (i) your Notice of Internet Availability of Proxy Materials (the “Notice”), (ii) your proxy card or voting instruction form in the enclosed proxy materials or (iii) the instructions that you received via email. Please refer to the additional logistical details and recommendations in the Proxy Statement. You may log-in to the Annual Meeting beginning at 8:15 a.m. Eastern Time on September 17, 2026.

The record date for the Annual Meeting is July 20, 2026 (the “Record Date”). Only stockholders of record as of the close of business on the Record Date may vote at the Annual Meeting. We will commence mailing the Notice to our stockholders on or about July 28, 2026, which will contain instructions on how to vote at the Annual Meeting as well as how to access the Proxy Statement and our 2026 Annual Report on Form 10-K.

It is important that your shares be represented at the Annual Meeting regardless of the size of your holdings. Whether or not you plan to attend the Annual Meeting, please provide your proxy by following the instructions described in the Proxy Statement.

Princeton, New Jersey

July 28, 2026

********************

If your shares are held in a brokerage account or with a bank or another nominee record holder, please be sure to mark your voting choices on the voting instruction form provided to you by your broker, bank, or other nominee. If you fail to specify your voting instructions, your shares will not be voted on certain proposals due to rules applicable to broker voting, and we may incur additional costs to solicit votes.

We are making this Proxy Statement and the accompanying form of proxy card, and our 2026 Annual Report on Form 10-K (the “Annual Report”), available electronically via the internet at ww www.virtualshareholdermeeting.com/GRCE2026 and our website, www.gracetx.com. If you wish to receive a paper or email copy of these documents, please follow the instructions contained in the Notice of Internet Availability of Proxy Materials (the “Notice”). There is no charge for requesting a copy.

The Notice will be mailed to our stockholders on or about July 28, 2026, in connection with the solicitation of proxies on behalf of our Board of Directors (our “Board”) for use at our 2026 Annual Meeting of Stockholders, to be held on September 17, 2026 at 8:30 a.m., Eastern Time, virtually at www.virtualshareholdermeeting.com/GRCE2026, and at any adjournment or postponement thereof (the “2026 Annual Meeting” or the “Annual Meeting”). Whether or not you plan to attend the Annual Meeting, please follow the instructions on the Notice so that your shares may be voted at the Annual Meeting. You may submit your proxy by mail, by telephone, or through the internet by following the instructions set forth on the Notice.

Except as otherwise indicated, references in this Proxy Statement to “Grace,” “Grace Therapeutics,” “the Company,” “we,” “us” and “our” refer to Grace Therapeutics, Inc. (formerly known as Acasti Pharma Inc.) and its consolidated subsidiary.

The information provided in the “question and answer” format below is for your convenience only and is merely a summary of the information contained in this Proxy Statement. You should read this entire Proxy Statement carefully.

The Annual Meeting is a virtual only meeting held through a live webcast at www.virtualshareholdermeeting.com/GRCE2026. You will not be able to attend the Annual Meeting in person.

You are entitled to attend and ask questions at the Annual Meeting if you were a stockholder as of the close of business on the Record Date (i.e., July 20, 2026). To be admitted to the Annual Meeting, you will need to visit www.virtualshareholdermeeting.com/GRCE2026 and enter the 16-digit Control Number found next to the label “Control Number” on your Notice, your proxy card, voting instruction form or in the email in which this Proxy Statement was sent to you. If you are a beneficial stockholder, you should contact the bank, broker, or other nominee where you hold your account well in advance of the Annual Meeting if you have questions about obtaining your Control Number or voting instruction form to vote.

Whether or not you attend the Annual Meeting, it is important that you submit your proxy so that your shares are voted at the Annual Meeting.

We encourage you to access the Annual Meeting before it begins. Online check-in will begin at 8:15 a.m. Eastern Time on September 17, 2026.

If you were not a stockholder as of the Record Date, or you do not log-in using your Control Number, you will be able to log-in as a guest by visiting www.virtualshareholdermeeting.com/GRCE2026 and registering as a guest. Please note that if you log-in as a guest, you will not be able to vote your shares or ask questions during the Annual Meeting.

Each stockholder entitled to vote at the Annual Meeting may cast one vote for each share of common stock owned by him, her or it that has voting power upon each matter considered at the Annual Meeting. Our stockholders do not have the right to cumulate their votes in the election of directors.

For Proposal No. 2, to approve, on an advisory basis, the compensation of our named executive officers, the affirmative vote of the majority of votes cast on this Proposal is required for approval. Abstentions and broker non-votes will be considered in determining whether a quorum is present and will have no effect on the outcome of Proposal 2.

For Proposal No. 3, to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2027, the affirmative vote of the majority of votes cast on this Proposal is required for approval. Abstentions will have no effect on the outcome of Proposal No. 3. There will be no broker non-votes with respect to Proposal No. 3.

For Proposal No. 4, to approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executive officers, the affirmative vote of the majority of votes cast on this Proposal is required for approval. Votes may be cast for 1 YEAR, 2 YEARS, 3 YEARS or ABSTAIN. The affirmative vote of the majority of votes cast on this Proposal is required for approval, however, because there are several voting choices with respect to this Proposal, it is possible that no single choice will receive a majority vote. Considering the foregoing, our Board will consider the outcome of the vote when determining the frequency of future advisory votes on executive compensation. Moreover, because this is an advisory vote, our Board has the discretion to determine the frequency of future advisory votes on executive compensation notwithstanding the results of the vote on this Proposal. Abstentions and broker non-votes will be considered in determining whether a quorum is present and will have no effect on the outcome of Proposal 4.

it is the intention of the persons named in the accompanying proxy card to vote on those matters in accordance with their best judgment to the extent authorized under Rule 14a-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

If on the Record Date your shares were registered directly in your name with our transfer agent, then you are a stockholder of record.

If you are a stockholder of record, your proxy is being solicited directly by us, and you may vote online during the Annual Meeting or vote prior to the Annual Meeting by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to vote prior to the Annual Meeting by proxy through the internet, over the telephone or by using a proxy card that you may request or that we may elect to deliver at a later time to ensure your vote is counted. You may still attend the Annual Meeting and vote at the Annual Meeting even if you have already submitted your proxy.

Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Nominee

If on the Record Date your shares were held indirectly (that is, you held your shares in “street name” in a brokerage account or with a bank or another nominee record holder), then you are a beneficial owner.

If you are a beneficial owner, a Notice or voting instruction form has been provided to you by your broker, bank or other nominee describing how to submit voting instructions for your shares.

If you are a stockholder of record, you may revoke your proxy by: (1) submitting a new proxy over the internet or by telephone or submitting another properly completed proxy card with a later date than your original card, but no later than (x) 11:59 p.m. on September 16, 2026 if you are submitting by mail and (y) 11:59 p.m. on September 16, 2026 if you are submitting by telephone or internet; or (2) voting at the Annual Meeting (note that simply attending the Annual Meeting will not, by itself, revoke your proxy). We will count your vote in accordance with the last instructions we receive from you prior to the closing of the polls.

If you are a beneficial owner, you should follow the instructions provided by your broker, bank, or other nominee.

“For,” “Against,” “Abstain” votes and broker non-votes; for Proposal No. 3, “For,” “Against,” and “Abstain” votes; and for Proposal No. 4, “1 Year,” “2 Years,” “3 Years,” “Abstain” votes and broker non-votes. An agent of Broadridge will tabulate the votes and serve as inspector of election for the Annual Meeting.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote at the Annual Meeting (see “Who can attend the Annual Meeting, and how do I attend?” above for details). Abstentions and broker non-votes will be counted towards the quorum requirement. If a quorum is not present or represented by proxy at the Annual Meeting, the Annual Meeting will be adjourned by either the chairperson of the meeting or by the vote of a majority in the voting power of the stockholders entitled to vote and present or represented by proxy, until a quorum is obtained. If an adjournment is for more than 30 days or a new record date is fixed for the adjourned meeting, we will provide notice of the adjourned meeting to each stockholder of record entitled to vote at the Annual Meeting.

In addition to voting online during the Annual Meeting or changing a vote you may have submitted previously by following the methods described in this Proxy Statement, stockholders who attend the Annual Meeting and log in using their Control Number will have an opportunity to submit questions online during a portion of the Annual Meeting. Instructions for submitting a question during the Annual Meeting will be provided on the Annual Meeting website. We will endeavor to answer as many submitted questions as time permits; however, we reserve the right to exclude questions regarding topics that are not pertinent to meeting matters or company business or are inappropriate. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition.

If you have difficulty accessing the Annual Meeting or experience technical difficulties during the Annual Meeting, please call the toll-free number that will be available on our virtual stockholder login site (www.virtualshareholdermeeting.com/GRCE2026) for assistance. Technicians will be available to help you with any technical difficulties you may have beginning 15 minutes prior to the start of the Annual Meeting, and technicians will be available through the conclusion of the Annual Meeting. Additional information regarding matters addressing technical and logistical issues, including technical support during the Annual Meeting, will be available on the Annual Meeting website.

to our stockholders entitled to notice of and to vote at the Annual Meeting, provided we have not included the exhibits to the Annual Report on Form 10-K. We will provide copies of the exhibits to Form 10-K upon request by eligible stockholders, provided we may impose a reasonable fee for providing such exhibits, which is limited to our reasonable expenses. Requests for copies of such exhibits should be mailed to our Corporate Secretary at Grace Therapeutics, Inc., 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540, Attn: Corporate Secretary.

Our Board currently consists of five directors, each serving a one-year term that will expire at the 2026 Annual Meeting.

Our Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), has nominated current directors Brian Davis, Vimal Kavuru, Prashant Kohli, George Kottayil and Edward Neugeboren for re-election to our Board, each to serve until the 2027 Annual Meeting and until such director’s successor is elected and qualified or until his earlier death, resignation, retirement, disqualification or removal.

Detailed biographical information for each of the nominees is provided in this Proxy Statement below under the heading “Director Nominees.” Except for Prashant Kohli, our Chief Executive Officer, each of the nominees has been determined by our Board to be independent.

If a nominee is unable or unwilling to serve, the shares to be voted for such nominee that are represented by proxies will be voted for any substitute nominee designated by our Board. We did not receive any stockholder nominations for director.

If a quorum is present at the Annual Meeting, the five nominees for director receiving a plurality of the votes cast by stockholders will be elected to serve as directors. As a result, withheld votes and broker non-votes will have no effect on the election of directors. If not otherwise specified, proxies will be voted “FOR ALL” of the nominees for director named above.

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR ALL” FOR THE ELECTION OF THE DIRECTOR NOMINEES NAMED ABOVE.

Pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and Section 14A of the Exchange Act, we are required to provide a stockholder advisory vote on the compensation of our named executive officers. This proposal, commonly known as “say-on-pay,” gives our stockholders the opportunity to express their views on the compensation of our named executive officers. The vote is advisory, and, therefore, it is not binding on the Board, the Compensation Committee, or us. Nevertheless, the Compensation Committee will consider the outcome of the vote when considering future executive compensation decisions. At our 2020 Annual Meeting of Stockholders, our stockholders indicated their preference for a “say-on-pay” vote to be held annually. Our Board subsequently determined that we would hold a “say-on-pay” vote on an annual basis until the next required vote on the frequency of such advisory votes, which is being held at the Annual Meeting.

Our executive compensation program is designed to attract, motivate and retain our named executive officers who are critical to our success. The Board believes that our executive compensation program is well tailored to retain and motivate key executives while recognizing the need to align our executive compensation program with the interests of our stockholders and our “pay-for-performance” philosophy. The Compensation Committee regularly reviews the compensation program for our named executive officers to ensure it achieves the desired goals of aligning our executive compensation structure with our stockholders’ interests and current market practices.

We encourage our stockholders to read the “Summary Compensation Table” and other related compensation tables and narrative disclosures in the “Executive Compensation” section of this Proxy Statement, which describe the compensation of our named executive officers for the fiscal year ended March 31, 2026.

We are asking our stockholders to vote on the following resolution:

RESOLVED, that the stockholders of Grace Therapeutics, Inc. approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2026 Annual Meeting of Stockholders pursuant to Item 402 of Regulation S-K, including the compensation tables and the narrative disclosures that accompany the compensation tables.

You may vote “FOR,” “AGAINST,” or “ABSTAIN” on Proposal 2. The vote required to approve Proposal 2 is governed by our Bylaws and is the affirmative vote of the majority of votes cast on this Proposal. As a result, abstentions and broker non-votes will have no effect on the outcome of Proposal 2. If not otherwise specified, proxies will be voted “FOR” Proposal 2.

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” PROPOSAL 2 TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT.

The Audit Committee has appointed KPMG LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2027, and has further directed that management submit the appointment of KPMG LLP as our independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. KPMG LLP has audited our financial statements since March 31, 2024. One or more representatives of KPMG LLP is expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our Bylaws or other governing documents or law require stockholder ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm. However, the Audit Committee is submitting the appointment of KPMG LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the appointment, the Audit Committee will reconsider its appointment of KPMG LLP but will not be required to take any action. Even if the appointment is ratified, the Audit Committee, in its discretion, may direct the appointment of different independent registered public accounting firm at any time during the year if the Audit Committee determines that such a change would be in the best interests of the Company and its stockholders.

The following table represents aggregate fees billed to the Company for the fiscal years ended March 31, 2026 and March 31, 2025 by KPMG LLP, the Company’s independent registered public accounting firm.

The Audit Committee’s charter provides that the Audit Committee pre-approve, or establish and maintain an appropriate policy governing the pre-approval of, all audit, audit-related and permissible non-audit and tax services to be provided to the Company by the independent auditor, in accordance with Section 10A of the Exchange Act and SEC rules.

All services for which fees were billed as described above were pre-approved by the Audit Committee. None of the services described above were approved by the Audit Committee pursuant to the de minimis exception during the fiscal years ended March 31, 2026, and March 31, 2025.

You may vote “FOR,” “AGAINST,” or “ABSTAIN” on Proposal 3. The vote required to approve Proposal 3 is governed by our Bylaws and is the affirmative vote of the majority of votes cast on this Proposal. As a result, abstentions will have no effect on the outcome of Proposal 3. There will be no broker non-votes with respect to Proposal No. 3. If not otherwise specified, proxies will be voted “FOR” Proposal 3.

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY’S INDEPENDENT REGISTERED

PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING MARCH 31, 2027.

In Proposal No. 2, we are providing our stockholders with the opportunity to vote to approve, on an advisory basis, the compensation of our named executive officers. In Proposal No. 4, we are asking our stockholders to cast a non-binding advisory vote regarding the frequency of future advisory votes on executive compensation. Stockholders may vote for a frequency of every one, two, or three years, or may abstain.

Under Exchange Act rules, the Company must hold an advisory, non-binding stockholder vote regarding the frequency of future “say-on-pay” votes at least once every six years.

After careful consideration, our Board believes that the executive compensation advisory vote should be held annually, and therefore our Board unanimously recommends that you vote for a frequency of 1 YEAR for future executive compensation advisory votes. While the Company’s executive compensation programs are designed to promote a long-term connection between pay and performance, the Board recognizes that compensation disclosures are made annually. Holding an annual advisory vote on executive compensation would establish the practice of stockholders providing the Company with more direct and immediate feedback on those compensation disclosures. However, stockholders should note that because the advisory vote on executive compensation occurs well after the beginning of the compensation year, and because the different elements of the Company’s executive compensation programs are designed to operate in an integrated manner and to complement one another, in many cases it may not be appropriate or feasible to change the Company’s executive compensation for such compensation year.

You may select “1 Year”, “2 Years,” “3 Years” or “Abstain” with respect to Proposal 4. The affirmative vote of the majority of votes cast on this Proposal is required for approval, however, because there are several voting choices with respect to this Proposal, it is possible that no single choice will receive a majority vote. In light of the foregoing, our Board will consider the outcome of the vote when determining the frequency of future advisory votes on executive compensation. Moreover, because this is an advisory vote, our Board has the discretion to determine the frequency of future advisory votes on executive compensation notwithstanding the results of the vote on this Proposal. Abstentions and broker non-votes will have no effect on the outcome of Proposal 4.

THE BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE “1 YEAR” AS THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

The following table sets out certain information regarding each of the nominees for election as director:

The following is a brief biography of our current directors, director nominees, and current executive officers:

Vimal Kavuru – Director Nominee and Chair of the Board. Mr. Kavuru, 57, has served as a director of Grace Therapeutics since August 2021. He has created and led several pharmaceutical companies. Mr. Kavuru brings, in his vision and management, a broad-based understanding of the global pharmaceutical industry with expertise in strategic planning, product and business development, and operations. In addition to previously serving as the Chairman of the board of Grace Therapeutics Inc., which was a private company acquired by Acasti Pharma, Inc., Mr. Kavuru is the Founder, Chairman and Chief Executive Officer of Rising Pharma Holdings, Inc., a U.S. generic pharmaceutical company, and Acetris Pharma Holdings, LLC, a generic pharmaceutical company serving U.S. government agencies, positions Mr. Kavuru has held since January 2013 and January 2016, respectively. Previously, Mr. Kavuru founded Citron Pharma and Lucid Pharma, each of which were sold to Aceto Corporation in 2016, Casper Pharma LLC, an emerging specialty brand pharmaceutical company, and Gen-Source RX, a national distributor of generic pharmaceuticals that was acquired by Cardinal Health in 2014. In 2007, Mr. Kavuru also co-founded Celon Labs, a specialty oncology and critical care pharmaceutical company that was acquired by Zanzibar Pharma Limited, a portfolio company of CDC Group. Mr. Kavuru was initially elected to the Board as a nominee of former shareholders of Grace Therapeutics (the private company) in connection with Acasti’s acquisition of Grace Therapeutics. He is a registered pharmacist in the state of New York, holds a B.S. in Pharmacy from HKE College of Pharmacy, Bulgarga, India, and attended Long Island University, Brooklyn, New York with specialization in industrial pharmacy. The Board believes that Mr. Kavuru’s management experience in the pharmaceutical industry, as well as his operational expertise, qualify him to serve on the Board.

A. Brian Davis – Director Nominee. Mr. Davis, 59, has nearly three decades of experience as a chief financial officer and other executive financial positions in commercial and development-stage publicly traded life science companies. Mr. Davis has extensive knowledge and background related to public company accounting and financial reporting rules and regulations as well as the evaluation of financial results, internal controls and business processes. Since October 2025, Mr. Davis has served as a financial consultant in the biotechnology industry. From December 2021 to October 2025, Mr. Davis was the Chief Financial Officer of XyloCor Therapeutics, Inc., a clinical-stage gene therapy company developing potential therapies for patients with cardiovascular disease. Mr. Davis was the Chief Financial Officer of Verrica Pharmaceuticals Inc., a publicly traded, NDA-stage dermatology therapeutics company, from October 2019 to July 2021. Prior to joining Verrica, Mr. Davis was the Chief Financial Officer of Strongbridge Biopharma plc, a public commercial-stage biopharmaceutical company, from March 2015 to September 2019. Mr. Davis was previously the Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company until December 2014, and Neose Technologies, Inc., a publicly traded biopharmaceutical company. Mr. Davis is licensed as a certified public accountant and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School of the University of Pennsylvania.

The Board believes Mr. Davis’ experience serving as the chief financial officer at several other publicly traded biopharmaceutical companies as well as his knowledge and keen understanding of the issues facing biopharmaceutical companies qualify him to serve on the Board.

S. George Kottayil, Ph.D. – Director Nominee. Dr. Kottayil, 63, has over two decades of experience in the pharmaceutical industry with specific expertise in product development and drug delivery. He has several approved patents to his credit and is an inventor on multiple FDA approved drug products, a few that have achieved significant success. He co-founded two pharmaceutical drug development and drug delivery technology companies and was CEO and a member of each of their boards of directors. Most recently, from October 2014, he co-founded and was CEO and director of Grace Therapeutics Inc., the private company acquired by Acasti Pharma, Inc. in August 2021. Dr. Kottayil served as Grace Therapeutics’ Chief Operating Officer from September 2021 to May 2023. Dr. Kottayil has held senior positions in product development, business operations, and general management at small to medium-sized life science companies, successfully advancing drug products from bench to FDA approval and launch. He directed business operations at Unimed Pharmaceuticals Inc., a division of Solvay Pharmaceuticals, now Abbvie, from January 1993 to June 2002, and played a key role in product development and obtaining FDA approval for the company’s NDA products. Dr. Kottayil graduated with a Ph.D. in Organic and Medicinal Chemistry from the University of Kentucky. The Board believes that Dr. Kottayil’s extensive industry and management experience, including his in-depth knowledge and leadership in successfully executing multiple pharmaceutical and clinical drug development programs that resulted in securing FDA approval, qualify him to serve on the Board.

Prashant Kohli – Chief Executive Officer and Director Nominee. Prashant Kohli, 54, has served as Grace Therapeutics’ Chief Executive Officer since April 2023 and previously served as Chief Commercial Officer from September 2022 to April 2023 and Vice President, Commercial Operations from August 2021 to August 2022. He has over 20 years of commercialization experience leading strategy, sales, marketing, and product management. Prior to joining the Company in August 2021, Mr. Kohli was Vice President, Commercial Operations of Grace Therapeutics Inc. (the private company) since December 2017. He has expertise crafting go-to-market plans for products with unique value proposition that address critical unmet needs. He has built, deployed, and led sales and marketing from the ground-up with considerable experience in organization design, recruiting, performance management, incentive compensation, and P&L accountability. He has successfully implemented evidence-based, consultative-selling model that is rooted in deep understanding of the health ecosystem including patients, providers, health systems, government, and payers. He has also designed strategic marketing plans that generate leads and increase share-of-voice, augmenting the salesforce with digital tactics that increase reach and frequency. He has extensive commercial experience with specialty and small molecule drugs including in rare and orphan diseases. Mr. Kohli has worked at Archi-Tech Systems, Cardinal Health, IMS Health, Rosenbluth, and Dun & Bradstreet. He has a B.A. in Computer Science and Math from Augustana College and an M.B.A. from The Wharton School of the University of Pennsylvania. The Board believes that Mr. Kohli’s extensive industry and management experience, including his experience as Chief Executive Officer of Grace Therapeutics, qualify him to serve on the Board.

Edward Neugeboren – Director Nominee. Mr. Neugeboren, 57, has over three decades of healthcare experience in pharmaceutical operations, business development, corporate management, investment banking, asset management, and institutional equity research. Since June 2013, Mr. Neugeboren has served as the Founder and Managing Partner of QuadView Healthcare Advisors, a healthcare investment banking and business development advisory firm. From January 2016 to October 2025, Mr. Neugeboren served as the Chief Strategy Officer of Cronus Pharma, LLC, a fully integrated R&D, manufacturing, and sales & marketing pharmaceutical company and at which Mr. Neugeboren is a principal. Mr. Neugeboren led Cronus Pharma’s commercial operations, strategic planning and acquisitions and was also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing. Since March 2025, Mr. Neugeboren has served on the Board of Directors of Matinas Biopharma, Inc. Previously, Mr. Neugeboren was the Chief Strategy Officer for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company, and Casper Pharma, LLC, a specialty pharmaceutical company. Mr. Neugeboren was previously a Managing Director of Ledgemont Capital Group, LLC, an investment banking firm providing strategic and financial advisory services to emerging healthcare and technology companies. Mr. Neugeboren was also a Managing Partner of Third Ridge Capital Management, LLC, a long/short U.S. equity hedge fund. Mr. Neugeboren holds Series 24, 7 and 63 FINRA security licenses and graduated with a BA in Economics from Union College. The Board believes Mr. Neugeboren’s extensive healthcare experience in pharmaceutical operations, including his experience as Chief Strategy Officer of Cronus Pharma, LLC, qualify him to serve on the Board.

As required under The Nasdaq Stock Market LLC (“Nasdaq”) listing standards, a majority of the members of a listed company’s board must qualify as “independent,” as affirmatively determined by the board. Our Board consults with the Company’s legal counsel to ensure that our Board’s determinations are consistent with relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent Nasdaq listing standards, as in effect from time to time.

Consistent with these considerations, after review of all relevant identified transactions and relationships between each director and nominee for director, or any of his or her family members, and the Company, its senior management and its registered independent public accounting firm, our Board has affirmatively determined that: (i) Mr. Davis, Mr. Kavuru, Mr. Neugeboren, and Dr. Kottayil are independent within the meaning of Nasdaq Rule 5605(a)(2); (ii) current Audit Committee members, Mr. Davis, Mr. Kavuru and Mr. Neugeboren meet the additional test for independence for audit committee members imposed by Rule 10A-3 under the Exchange Act and Nasdaq Rule 5605(c)(2)(A); and (iii) current Compensation Committee members, Mr. Davis, Mr. Kavuru and Mr. Neugeboren meet the additional test for independence for compensation committee members imposed by Rule 10C-1 under the Exchange Act and Nasdaq Rule 5605(d)(2)(A). In making these determinations, our Board considered the relationships that each director and nominee for director has with us and all other facts and circumstances that our Board deemed relevant in determining their independence, including the beneficial ownership of our common stock by each person and such person’s affiliated entities, and any agreements or arrangements between us and any of our directors and director nominees or their affiliated entities.

There are no family relationships between any of our executive officers, directors, or director nominees.

The roles of our Board Chair and our principal executive officer are held by two different individuals, as we seek to maintain an appropriate balance between management and our Board. Our Board currently has an independent Chair of the Board, Mr. Kavuru, who has the authority, among other things, to preside over meetings of the Board and meetings of stockholders, work with the Chief Executive Officer to develop and approve an appropriate Board meeting schedule and meeting agendas, develop the agenda and moderate executive sessions of the independent members of the Board, act as principal liaison between the independent members of the Board and the Chief Executive Officer, to convene meetings of the independent members of our Board as appropriate and be available for consultation and direct communication with stockholders as deemed appropriate. Accordingly, our Board Chair has substantial ability to shape the work of our Board. The Company believes that separation of the positions of Board Chair and principal executive officer reinforces the independence of our Board in its oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Board Chair creates an environment that is conducive to objective evaluation and oversight of management’s performance, increasing management accountability and improving the ability of our Board to monitor whether management’s actions are in the best interests of the Company and its stockholders. As a result, the Company believes that having an independent Board Chair can enhance the effectiveness of our Board as a whole.

The Board is committed to the achievement of business success and the enhancement of long-term stockholder value with the highest standards of integrity and ethics. The Board as a whole has responsibility for risk oversight, with more in-depth oversight of certain areas of risk being conducted by the relevant Board committees that report on their deliberations to the full Board. The Board and its committees fulfill their oversight responsibilities supported by management, whose reporting processes are designed to provide information to the Board about the identification, assessment and management of critical risks and management’s risk mitigation strategies. Areas of risk evaluated include research and development, patents, commercial matters, human resources, cybersecurity, funding, regulatory matters, operational risks, financial (accounting, liquidity, and tax) matters, legal compliance, compensation, competitive risks and health, safety, and reputational risks, among others.

The standing committees of the Board oversee risks associated with their respective principal areas of focus. The Audit Committee’s role includes oversight of significant business risks, including financial, operational, business continuity, legal, regulatory, and reputational risks. The Audit Committee also oversees privacy, information

technology and security and cybersecurity risk exposures. The Compensation Committee is responsible for overseeing risks and exposures associated with our compensation programs and arrangements, including our executive and director compensation programs and arrangements. The Nominating and Corporate Governance Committee oversees risks relating to our corporate governance matters and policies and director succession planning. The full Board oversees CEO and senior management succession planning and overseeing management development.

Our Board has three standing committees: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. Each committee has adopted a written committee charter, which are available on the Company’s website at https://www.gracetx.com/investors.

The current composition of each of our Board’s committees is set forth in the following table:

Our Board held 18 meetings during fiscal year 2026, and each director attended at least 75% of (i) the number of Board meetings held during the period for which he was a director and (ii) the total number of committee meetings held during the period for which he served on each such committee.

In fiscal year 2026, the Audit Committee met four times, the Compensation Committee met once, and the Nominating and Corporate Governance Committee did not meet. All the Company’s then-serving directors attended the 2025 Annual Meeting of Stockholders. It is our policy to invite directors to attend the annual meetings of stockholders.

The primary purpose of our Audit Committee is to oversee and monitor the Company’s accounting and financial reporting processes and the integrity and audit of its financial statements. For this purpose, the Audit Committee performs several functions. The principal duties and responsibilities of our Audit Committee include, among other things:

Our Board has determined that Mr. Davis qualifies as an “audit committee financial expert,” as defined in applicable SEC rules. Our Board made a qualitative assessment of the level of knowledge and experience of Mr. Davis based on a number of factors. In its assessment of Mr. Davis, the Board considered his formal education and his experience as chief financial officer of other public companies.

The primary purpose of our Compensation Committee to oversee the Company’s compensation policies, plans and programs, to review and determine (or recommend to our Board for approval) the compensation to be paid to the Company’s executive officers and directors, including, among other things:

Generally, compensation of our executive officers and non-employee directors is recommended to our Board by the Compensation Committee. Annually, the Compensation Committee conducts a formal review and assessment of

executive and corporate performance. The Compensation Committee is currently composed of Mr. Kavuru (Chair), Mr. Davis, and Mr. Neugeboren, each of whom is independent within the meaning of applicable Nasdaq rules.

Our executive compensation program is intended to attract, motivate and retain high-performing senior executives, encourage and reward superior performance, and align the executives’ interests with ours as well as our stockholders by providing compensation that is competitive with the compensation received by executives employed by comparable companies, and ensuring that the achievement of annual objectives is rewarded through the payment of bonuses, and providing executives with long-term incentives through the grant of stock options.

The Compensation Committee has authority to retain the services of independent compensation consultants to advise its members on executive and non-employee director compensation and related matters, and to determine the fees and the terms of the engagement of those compensation consultants. During the fiscal year ended March 31, 2026, the Compensation Committee retained compensation consulting services from Pearl Meyer & Partners, LLC (“Pearl Meyer”) to review our executive compensation programs. Pearl Meyer also reviewed non-employee director compensation. All the services provided by Pearl Meyer were provided to the Compensation Committee. The Compensation Committee assessed the independence of Pearl Meyer and concluded that its engagement of Pearl Meyer did not raise any conflict of interest with the Company or any of its directors or executive officers.

The Compensation Committee establishes management compensation policies and oversees their general implementation. All members of the Compensation Committee have direct experience that is relevant to their responsibilities as Compensation Committee members. All Compensation Committee members are or have held senior executive or director roles within significant businesses in our industry, some also have public companies experience, and have a level of financial understanding which allows them to assess the costs versus benefits of compensation plans. The Compensation Committee’s members’ combined experience in our sector provides them with a good understanding of our success factors and risks, which are highly relevant to determining metrics for measuring success.

The primary purpose of our Nominating and Corporate Governance Committee is to oversee aspects of the Company’s corporate governance functions, including among other things:

The selection of the nominees for the Board is made by the Board, based on the recommendation of the Nominating and Corporate Governance Committee. As described further in the Corporate Governance Guidelines, candidates nominated for election or reelection to the Board must possess the following minimum characteristics:

In the case of incumbent directors whose terms of office are set to expire, we review such directors’ overall service to the Company during their term of office, including the number of meetings attended, level of participation, quality of performance and any transactions of such directors with the Company during their term of office.

We may use various sources to identify the candidates for the Board, including its own contacts and the references of our other directors, officers, advisors, and executive placement agencies. The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders and will evaluate director candidates in the same manner in which it evaluates candidates recommended by other sources, including the minimum criteria set forth above.

Stockholders who wish to nominate a candidate for election to our Board may do so by delivering a written notice to the Nominating and Corporate Governance Committee at the Company’s principal executive offices: Grace Therapeutics, Inc., 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540, Attn: Secretary, not later than the close of business on the 90^th day, nor earlier than 120^th day, prior to the first anniversary of the preceding year’s annual meeting of stockholders. However, in the event that the date of the annual meeting of stockholders is more than 30 days before or more than 70 days after such anniversary date, notice by the stockholder must be so delivered not earlier than the 120^th day prior to such annual meeting and not later than the close of business on the later of the 90^th day prior to such annual meeting or the 10^th day following the day on which public announcement of the date of such meeting is first made by the Company. Submissions must include, among other things, the full name of the proposed nominee, a description of the proposed nominee’s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee’s qualifications as a director and the name and address of the stockholder on whose behalf the submission is made and the number of shares of common stock owned beneficially by such stockholder. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. Stockholders are advised to review the Bylaws which contain a description of the information required to be submitted, as well as additional requirements about advance notice of director nominations. In addition to satisfying the foregoing advance notice requirements under the Bylaws, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide written notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than July 19, 2027, which is 60 days prior to the one-year anniversary of this year’s Annual Meeting.

The Board has not adopted any formal written director term limit policy.

Any stockholder who wishes to address questions regarding the business or affairs of Grace Therapeutics directly with the Board, or any individual director, should direct such stockholder’s questions in writing to the Chair of the Board, or any individual director by name, at Grace Therapeutics, Inc., 103 Carnegie Center Suite 300, Princeton, New Jersey 08540. Upon receipt of any such communications, the correspondence will be directed to the appropriate person, including individual directors.

We have adopted an Insider Trading Policy and related procedures governing the purchase, sale, and other dispositions of our securities by our directors, officers, and employees. We believe our Insider Trading Policy and related procedures are reasonably designed to promote compliance with insider trading laws, rules and regulations, and the listing standards applicable to us. Our Insider Trading Policy is filed as an exhibit to our Annual Report on Form 10-K for the year ended March 31, 2026. In addition, transactions by us in our own securities are entered into after evaluation by our legal counsel for compliance with applicable securities laws.

Our Insider Trading Policy prohibits our directors and employees, including our executive officers, from engaging in any hedging transactions involving Company securities including through the use of financial instruments such as forward sale or purchase contracts, equity swaps, collars, exchange funds or other transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company securities.

The Board has adopted an Incentive Compensation Recovery Policy as required by Rule 10D-1 under the Exchange Act and the corresponding Nasdaq listing standards. Under the Incentive Compensation Recovery Policy, in the event of certain accounting restatements, we will be required to recover erroneously received incentive-based compensation from our current and former executive officers. In the event of such an accounting restatement, we will be required to recover the amount of incentive compensation received by a covered executive that exceeds the amount that otherwise would have been received if that incentive compensation had been determined based on the restated amounts, without regard to any taxes paid. A copy of the Incentive Compensation Recovery Policy is filed as an exhibit to our Annual Report on Form 10-K for the year ended March 31, 2026.

The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended March 31, 2026, with management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the Securities and Exchange Commission. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the Audit Committee concerning independence and has discussed with the independent registered public accounting firm the accounting firm’s independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the Company’s audited financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026.

A. Brian Davis, Chair

Vimal Kavuru

Edward Neugeboren

Our current executive officers, and their respective ages as of July 20, 2026, are as follows:

Prashant Kohli – Please see above biography included in “Director Nominees.”

Robert J. DelAversano – Vice President, Finance (Principal Financial Officer and Principal Accounting Officer). Mr. DelAversano, 55, is a certified public accountant and has over 27 years of experience in accounting including 13 years in public accounting. Mr. DelAversano joined the Company in November 2023 as Vice President, Finance and serves as the principal financial officer and principal accounting officer. From 2018 to July 2023, Mr. DelAversano worked in roles of increasing seniority at OncoSec Medical Incorporated (“OncoSec”), a clinical-stage immuno-oncology company, in positions including Vice President of Finance, Principal Accounting Officer and Controller, and Executive Director of Finance, where he had global responsibility for accounting, external financial reporting and financial controls covering all aspects of OncoSec’s business. Prior to joining OncoSec, Mr. DelAversano was the Director of Financial Reporting and Taxation at Brio Financial Group (“Brio”), consulting with various public companies in financial reporting, internal control development and evaluation, budgeting, and forecasting. Prior to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC and oversaw its accounting and tax practice with industry focuses in manufacturing, wholesalers, and medical devices services. Mr. DelAversano received a B.S. in Accounting from Rider University.

Dr. R. Loch Macdonald – Chief Medical Officer. Dr. Macdonald, 65, has served as the Company’s Chief Medical Officer since May 2023. Dr. Macdonald is a world-renowned practicing neurosurgeon-scientist and respected authority in subarachnoid hemorrhage. Dr. Macdonald acted as Professor, Department of Surgery, Division of Neurosurgery at the University of Toronto from January 2007 until December 2019, and was Head, Division of Neurosurgery, St. Michael’s Hospital, University of Toronto from January 2007 until December 2015. He was Professor, Department of Neurological Surgery, Barrow Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, from April 2018 until August 2018; Fellow, Department of Neurosurgery, University of Illinois Hospitals in Chicago, Illinois from December 2018 until June 2019; Clinical Professor, Department of Neurological Surgery, University of California Fresno, in Fresno, California from July 2019 until September 2021; and from October 2021 to the present has been Neurosurgeon, Community Physicians Group, Community Neurosciences Institute, Community Regional Medical Center and Medical Director of Neurosciences Research, Community Health Partners. Dr. Macdonald was also a founder of Edge Therapeutics, Inc. in 2009, where he was a member of the board of directors between 2009 and 2018 and was Chief Scientific Officer between 2011 and 2018. Dr. Macdonald completed his medical degree at the University of British Columbia, Vancouver, British Columbia, and his Ph.D. in Experimental Surgery at the University of Alberta in Edmonton, Alberta. He completed his Neurosurgery residency at the University of Toronto.

Amresh Kumar – Vice President, Program Management. Mr. Kumar, 47, has served as the Company’s Vice President, Program Management since May 2023. Mr. Kumar is an experienced drug development, chemistry, manufacturing and controls (CMC) and program management expert supporting investigational and marketed products for rare diseases and neurology. Mr. Kumar is the former product leader of GTx-104 while at Grace Therapeutics, the private company acquired by Acasti Pharma Inc. in August 2021. Mr. Kumar acted as the Sr. Director of Program Management at Foresee Pharmaceuticals Inc. from April 2022 until May 2023 and as Program Leader and Associate Director - R&D at Grace Therapeutics between March 2015 and January 2022. Mr. Kumar received a Ph.D. in Pharmaceutical Science from Sunrise University, India, focusing on complex injectable drug delivery systems of highly soluble oncology drugs. He has published many research articles and has more than ten granted patents and many patent applications worldwide to his credit.

The following table sets forth certain information regarding the ownership of the Company’s common stock as of July 20, 2026, by: (i) each current director and director nominee; (ii) each of the named executive officers in the “Summary Compensation Table”; (iii) all current executive officers and directors of the Company as a group; and (iv) all those known by the Company to be beneficial owners of more than five percent of its common stock. Applicable percentages are based on 16,274,026 shares of common stock outstanding on July 20, 2026.

Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including options and warrants that are currently exercisable or exercisable within 60 days of July 20, 2026. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose.

Common stock subject to stock options and warrants currently exercisable or exercisable within 60 days of July 20, 2026 are deemed to be outstanding for computing the percentage ownership of the person holding such options and/or warrants and the percentage ownership of any group of which the holder is a member but are not deemed outstanding for computing the percentage of any other person.

Our named executive officers (“NEOs”) for the fiscal year ended March 31, 2026 (“Fiscal Year 2026”) are:

The following table sets forth information regarding compensation awarded or paid to, or earned by, our NEOs with respect to the years ended March 31, 2026, and March 31, 2025.

The annual base salary for each of our NEOs for Fiscal Year 2026 is listed in the table below:

Messrs. Kohli and Kumar and Ms. D’Andrea were each eligible to receive an annual performance bonus based on the achievement of corporate objectives as determined by our Board of Directors or Compensation Committee. Each executive officer is assigned a target bonus expressed as a percentage of his or her base salary. The target bonus amounts for Fiscal Year 2026 were as follows: 50% for Mr. Kohli and 30% for each of Mr. Kumar and Ms. D’Andrea. Actual performance bonus payments under the program were 0-100% of the target bonus amount based on the level of achievement of corporate objectives for the year, as determined by our Board of Directors or Compensation Committee. For Fiscal Year 2026, the corporate objectives principally consisted of corporate milestones related to the submission and FDA acceptance for review of the new drug application for our lead product candidate, GTx-104, and our continued support of the FDA’s review, including responding to information requests from the FDA during the review period. In the second calendar quarter of 2026, the Board of Directors

assessed the level of achievement of the program objectives and awarded Messrs. Kohli and Kumar and Ms. D’Andrea a performance bonus equal to 100% of target based on having met expectations for achievement of corporate objectives. Actual bonus amounts paid with respect to Fiscal Year 2026 performance are reflected in the “Non-Equity Incentive Plan Compensation” column of the Summary Compensation Table above.

In April 2025, our Board approved, upon recommendation of the Compensation Committee, time-vesting stock options to our NEOs vesting quarterly in substantially equal installments over a 36-month period, with an exercise price of $2.08 per share, and subject to the terms and conditions of the Grace Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”). Such exercise price is equal to the closing price of the Company’s shares on the grant date.

We do not have any pension benefit plans.

We have implemented a 401K plan for our employees. Because of the small size of our current employee population and to assure passage of anti-discrimination testing, the 401K plan has a “safe harbor” provision which provides a contribution of 3% of salary to the 401K accounts of all eligible employees, including NEOs.

Our executive employee benefit program also includes life, medical, dental and disability insurance. These benefits and perquisites are designed to be competitive overall with equivalent positions in comparable organizations.

On August 12, 2024, we entered into an employment agreement with Mr. Kohli, (the “CEO Letter Agreement”). Pursuant to the CEO Letter Agreement, Mr. Kohli is entitled to receive an annual base salary of $500,000 and an annual discretionary bonus of up to 50% of his annual base salary as determined by our Board. To earn the bonus, Mr. Kohli must remain employed with us throughout the year for which the bonus is paid and must be actively employed in good standing on the date in which the bonus is paid.

In addition, the CEO Letter Agreement provides that, subject to approval by our Board, Mr. Kohli may be granted from time to time an option to purchase shares of common stock with a price per share equal to the fair market value of the common stock, as determined by our Board at the time of the grant, which will be conditioned upon (a) Mr. Kohli’s continued employment with the Company at the time of the grant, (b) entering into an option agreement and (c) any other terms and conditions set forth in our equity incentive plan, the applicable option agreement and as may be determined by our Board in its sole discretion at the time of grant.

The term of the CEO Letter Agreement commenced on August 12, 2024, and continues until terminated in accordance therewith. Either we or Mr. Kohli may terminate the CEO Letter Agreement at any time, upon advanced written notice. The CEO Letter Agreement also imposes certain confidentiality, non-competition and non-solicitation obligations on Mr. Kohli during the term of the Letter CEO Agreement and for a specified time thereafter. The CEO Letter Agreement provides for standard benefits, such as paid vacation and participation in our employee benefit plans and programs.

On November 12, 2025, we entered into an amendment to the CEO Letter Agreement with Mr. Kohli, which supersedes certain of the severance terms contained in the CEO Letter Agreement (the “CEO Amendment No. 1”). On January 10, 2026, we entered into a further amendment to the CEO Letter Agreement with Mr. Kohli, which supersedes certain of the severance terms contained in the CEO Amendment No. 1 (“CEO Amendment No. 2”). Pursuant to CEO Amendment No. 2, if Mr. Kohli’s employment is terminated by us without Cause (as defined in the CEO Amendment No. 2), absent a Change in Control (as defined in the 2024 Plan) of our company, Mr. Kohli is entitled to receive accrued but unpaid salary, unreimbursed expenses, and benefits (collectively, the “Accrued Obligations”) owed to him and, subject to the execution, delivery and non-revocation of a general release of claims, we will (i) pay Mr. Kohli a continuation of his base salary then in effect for 12 months, and (ii) pay or reimburse Mr. Kohli for his COBRA premiums for 12 months on terms no less favorable than those in effect on the date of the CEO Amendment No. 2. Any unvested and outstanding equity awards held by Mr. Kohli shall be forfeited upon a termination by us without Cause absent a Change in Control of our company. The CEO Amendment No. 2 further provides if Mr. Kohli’s employment is terminated by us without Cause or if Mr. Kohli resigns for Good Reason (as defined in the CEO Amendment No. 2) in connection with or within 12 months following a Change in Control of our company, Mr. Kohli is entitled to receive the Accrued Obligations owed to him and, subject to the execution, delivery and non-revocation of a general release of claims, we will (i) pay Mr. Kohli a cash payment equal to 18 months of his base salary plus target bonus then in effect, and (ii) pay or reimburse Mr. Kohli for his COBRA premiums for 18 months on terms no less favorable than those in effect on the date of the CEO Amendment No. 2. Any unvested and outstanding equity awards held by Mr. Kohli shall be fully vested and exercisable upon such termination or resignation, as the case may be, in connection with or within twelve (12) months following a Change in Control of our company.

On November 12, 2025, we entered into an employment agreement with Amresh Kumar (the “Kumar Letter Agreement”), pursuant to which he is entitled to an annual salary of $310,000 and is eligible to receive annual performance bonuses of up to 30% of his annual base salary as determined by us in our sole discretion.

On January 10, 2026, we entered into an amendment to the Kumar Letter Agreement with Mr. Kumar, which supersedes certain of the severance terms contained in the Kumar Letter Agreement (the “Kumar Amendment”). Pursuant to the Kumar Amendment, if Mr. Kumar’s employment is terminated by the Company without Cause (as defined in the Kumar Amendment), absent a Change in Control of our company, Mr. Kumar is entitled to receive the Accrued Obligations owed to him and, subject to the execution, delivery and non-revocation of a general release of claims, the we will (i) pay Mr. Kumar a continuation of his base salary then in effect for 6 months, and (ii) pay or reimburse Mr. Kumar for his COBRA premiums for 6 months on terms no less favorable than those in effect on the date of the Kumar Amendment. Any unvested and outstanding equity awards held by Mr. Kumar shall be forfeited upon termination by us without Cause absent a Change in Control of our company. The Kumar Amendment further provides if Mr. Kumar’s employment is terminated by us without Cause or if Mr. Kumar resigns for Good Reason (as defined in the Kumar Amendment) in connection with or within 12 months following a Change in Control of our company, Mr. Kumar is entitled to receive the Accrued Obligations owed to him and, subject to the execution, delivery and non-revocation of a general release of claims, we will (i) pay Mr. Kumar a cash payment equal to 6 months of his base salary plus target bonus then in effect, and (ii) pay or reimburse Mr. Kumar for his COBRA premiums for 6 months on terms no less favorable than those in effect on the date of the Kumar Amendment. Any unvested and outstanding equity awards held by Mr. Kumar shall be fully vested and exercisable upon such termination or resignation, as the case may be, in connection with or within 12 months following a Change in Control of our company.

On November 12, 2025, we entered into an employment agreement with Carrie D’Andrea (the “D’Andrea Letter Agreement”), pursuant to which she is entitled to an annual salary of $310,000 and is eligible to receive annual performance bonuses of up to 30% of her annual base salary as determined by us in our sole discretion.

On January 10, 2026, we entered into an amendment to the D’Andrea Letter Agreement with Ms. D’Andrea, which supersedes certain of the severance terms contained in the D’Andrea Letter Agreement (the “D’Andrea Amendment”). Pursuant to the D’Andrea Amendment, if Ms. D’Andrea’s employment is terminated by us without Cause (as defined in the D’Andrea Amendment), absent a Change in Control of our company, Ms. D’Andrea is entitled to receive the Accrued Obligations owed to her and, subject to the execution, delivery and non-revocation of a general release of claims, we will (i) pay Ms. D’Andrea a continuation of her base salary then in effect for 6 months, and (ii) pay or reimburse Ms. D’Andrea for her COBRA premiums for 6 months on terms no less

favorable than those in effect on the date of the D’Andrea Amendment. Any unvested and outstanding equity awards held by Ms. D’Andrea shall be forfeited upon a termination by us without Cause absent a Change in Control of our company. The D’Andrea Amendment further provides if Ms. D’Andrea’s employment is terminated by us without Cause or if Ms. D’Andrea resigns for Good Reason (as defined in the D’Andrea Amendment) in connection with or within 12 months following a Change in Control of our company, Ms. D’Andrea is entitled to receive the Accrued Obligations owed to her and, subject to the execution, delivery and non-revocation of a general release of claims, we will (i) pay Ms. D’Andrea a cash payment equal to 6 months of her base salary plus target bonus then in effect, and (ii) pay or reimburse Ms. D’Andrea for her COBRA premiums for 6 months on terms no less favorable than those in effect on the date of the D’Andrea Amendment. Any unvested and outstanding equity awards held by Ms. D’Andrea shall be fully vested and exercisable upon such termination or resignation, as the case may be, in connection with or within twelve (12) months following a Change in Control of our company.

Ms. D’Andrea’s employment with the Company was terminated effective June 5, 2026. In connection with her separation from our company, Ms. D’Andrea executed a separation agreement, dated June 17, 2026, pursuant to which Ms. D’Andrea received certain severance benefits consistent with the D’Andrea Letter Agreement, as amended by the D’Andrea Amendment, conditioned upon her release of claims in favor of us, compliance with certain continuing obligations, including the non-competition and non-solicitation covenants of the D’Andrea Letter Agreement, and her obligations under her confidentiality of information and ownership of proprietary property agreement with us. Ms. D’Andrea also entered into a Consulting Agreement (the “Consulting Agreement”) with us, dated June 5, 2026, pursuant to which she agreed to provide certain consulting services to us for a consulting fee of $250 per hour for a period of 12 months. In addition, during the term of the Consulting Agreement, any stock option awards that Ms. D’Andrea received during her employment by us will continue to vest and will remain exercisable pursuant to the terms and conditions of the underlying equity plans as long as Ms. D’Andrea is providing services (or is willing to provide services) under the Consulting Agreement. Ms. D’Andrea will have 90 days from the termination of the Consulting Agreement to exercise any vested stock options.

Pursuant to their respective letter agreements, each of the NEOs is entitled to certain severance compensation in connection with certain events of termination, including after a change of control of our company. See “—Narrative to Summary Compensation Table—Employment Agreements with Named Executive Officers” above for a description of such payments.

The following tables provide information about the number and value of the outstanding stock option awards held by the NEOs as of March 31, 2026:

 

 

The following table shows information with respect to the compensation of our non-employee directors who served on our Board during Fiscal Year 2026:

Our non-employee director compensation program was established based on the advice and input of our independent compensation consultant, Pearl Meyer, to, among other matters, enable us to attract and retain qualified directors. Periodically, our Compensation Committee engages Pearl Meyer to review our director compensation program and the practices of similarly situated public life science companies to seek to align our director compensation with the compensation levels of such companies.

Consistent with the recommendation of Pearl Meyer, our Board adopted an updated non-employee director compensation policy in January 2026:

Following their first election or appointment to the Board, non-employee directors are eligible to receive an initial equity grant of 20,000 stock options vesting over a three-year period, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting over the subsequent two-year period in substantially equal monthly installments, subject to the other terms and conditions of the 2024 Plan. In addition to their initial grant, non-employee directors are eligible to receive an annual equity grant of 10,000 stock options with one half vesting immediately and the remaining one half vesting monthly in equal installments over a 12-month period. With respect to the annual option award the non-employee directors received on January 8, 2026, 25% of such option award

vested on the date of grant and the remaining 75% of such option award shall vest in substantially equal monthly installments on the 30th day of each month until September 30, 2026

Mr. Kohli does not receive any additional compensation for his service as a director. Information regarding the compensation for Mr. Kohli is reflected in the “—Summary Compensation Table” set forth above in this Proxy Statement.

The following table provides certain information with respect to all the Company’s equity compensation plans in effect as of March 31, 2026.

In addition to the Company’s Code of Conduct and Ethics, which serves as the primary guide to avoiding circumstances that may create a conflict, or the appearance of a conflict, between the personal interests of related persons and the interests of the Company, the Board has adopted a written policy with respect to the review, approval or disapproval and/or ratification of related party transactions. Under the policy, the Audit Committee is responsible for reviewing and approving or disapproving related party transactions. During its review and approval of related party transactions, the Audit Committee will consider the relevant facts and circumstances to decide whether to approve such transactions. In particular, the policy requires the Audit Committee to consider, among other factors:

The Audit Committee may only approve those transactions that are in, or are not inconsistent with, the Company’s best interests and those of its stockholders, as the Audit Committee determines in good faith. In addition, under the Company’s Code of Conduct and Ethics, the Company’s employees, directors, and director nominees have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.

Below is a description of transactions in which the Company was or will be a participant, in which the amount involved in the transaction (or series of related transactions) exceeded $120,000, and in which any of the Company’s directors, executive officers or beneficial owners of more than 5% of the Company’s common stock or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest since April 1, 2024, other than employment, compensation, termination, indemnification and change in control arrangements with the Company’s Named Executive Officers, which are described under the “Executive Compensation” section of this Proxy Statement.

On February 11, 2025, the Company sold in a private placement (the “2025 Private Placement”) an aggregate of 3,252,132 shares of common stock, at a purchase price of $3.395 per share (the “Shares”), and pre-funded warrants to purchase up to 1,166,160 shares of common stock, at a purchase price equal to the purchase price per Share less $0.0001 (the “2025 Pre-Funded Warrants”). Each 2025 Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share, is exercisable immediately and will expire once exercised in full. The net proceeds to the Company were approximately $13.5 million, after deducting fees and expenses.

For each Share and 2025 Pre-Funded Warrant issued, the Company sold and issued to each purchaser an accompanying common warrant to purchase shares of common stock (or 2025 Pre-Funded Warrants in lieu thereof), exercisable for an aggregate of 4,418,292 shares of common stock (or 2025 Pre-Funded Warrants in lieu thereof) (the “2025 Common Warrants”). Each 2025 Common Warrant is exercisable for one share of common stock at an exercise price of $3.395 per share, is immediately exercisable and will expire on the earlier of (i) the 60th day after the date the Food and Drug Administration (“FDA”) approves the New Drug Application (“NDA”) for the Company’s product candidate GTx-104, and (ii) September 25, 2028.

The 2025 Private Placement included the issuance of common stock, 2025 Pre-Funded Warrants, and 2025 Common Warrants to related parties namely (i) Shore Pharma LLC, an entity held in a trust for the benefit of immediate family members of Vimal Kavuru, the Chair of the Company’s Board of Directors and (ii) ADAR1 Partners, LP, AIGH Investment Partners, LP, and SS Pharma LLC, each a beneficial owner of more than 5% of the common stock prior to the 2025 Private Placement, resulting in gross proceeds of approximately $5.7 million.

The Company’s Certificate of Incorporation contains provisions that limit the liability of the Company’s directors and officers for monetary damages to the fullest extent permitted by the General Corporate Law of the State of Delaware (“DGCL”). In addition, if the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Company’s directors and officers will be further limited to the greatest extent permitted by the DGCL.

The Company’s Bylaws provide that the Company will indemnify its directors and officers, and may indemnify its employees, agents, and any other persons, to the fullest extent permitted by the DGCL, subject to limited exceptions. The Company’s Bylaws also provide that the Company must advance expenses incurred by or on behalf of a current or former director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.

Further, the Company has entered into indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements require the Company, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Company to advance all expenses reasonably and actually incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding. The Company believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. Directors’ and officers’ liability insurance has been purchased for the benefit of the Company’s directors and officers to back up the Company’s indemnification of them against liability incurred in their capacity as directors and officers, subject to certain limitations under applicable law. The Company also maintains insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits, or proceedings to which they are parties by reason of being or having been directors or officers of the Company. The coverage provided by these policies may apply whether or not the Company would have the power to indemnify such person against such liability under the provisions of the DGCL.

If you wish to propose a matter for consideration at the 2027 Annual Meeting, then the proposal must be received at our principal executive offices at Grace Therapeutics, Inc., 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540, Attn: Corporate Secretary and in compliance with the requirements set forth below.

For a stockholder proposal to be eligible under Rule 14a-8 of the Exchange Act for consideration at the 2027 Annual Meeting, such proposal must be received, along with proof of ownership of our common stock, no later than March 30, 2027, the date that is 120 calendar days prior to the first anniversary of the date this Proxy Statement was first released to stockholders. This date will change if the date of the 2027 Annual Meeting is more than 30 calendar days earlier or later than September 17, 2027.

In addition, our Bylaws establish an advance notice procedure for nominations for election to our Board and other matters that stockholders wish to present for action at an annual meeting other than those to be included in our proxy statement. In general, notice must be received not later than the close of business on the 90th day nor earlier than the 120th day prior to the first anniversary of the 2026 Annual Meeting. Therefore, to be presented at the 2027 Annual Meeting, we must receive such notice no earlier than the close of business on May 20, 2027 and no later than the close of business on June 19, 2027. However, if the date of the 2027 Annual Meeting is more than 30 days before or more than 70 days after the first anniversary of the 2026 Annual Meeting, notice by the stockholder must be so delivered not earlier than the 120th day prior to the 2027 Annual Meeting and not later than the close of business on the later of the 90th day prior to the 2027 Annual Meeting or the 10th day following the day on which public announcement of the date of the 2027 Annual Meeting is first made. Stockholders are advised to review our Bylaws, which also specify requirements as to the form, content, and manner of delivery of a stockholder’s notice.

In addition to satisfying the foregoing advance notice requirements under the Bylaws, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide written notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than July 19, 2027, which is 60 calendar days prior to the one-year anniversary of this year’s Annual Meeting. If the date of the 2027 Annual Meeting is more than 30 calendar days earlier or later than September 17, 2027, such notice must instead be provided by the later of 60 calendar days prior to the date of the 2027 Annual Meeting or the 10th calendar day following public announcement by us of the date of the 2027 Annual Meeting.

We have adopted a procedure, approved by the SEC, called “householding.” Under this procedure, stockholders of record who have the same address and last name will receive only one copy of the Notice and, if applicable, a printed version of this Proxy Statement and our Annual Report, unless we are notified that one or more of these stockholders wishes to receive individual copies. This procedure reduces our printing costs and postage fees.

If you are eligible for householding, but you and other stockholders of record with whom you share an address currently receive multiple copies of the Notice, or if you hold our stock in more than one account, and in either case you wish to receive only a single copy of the Notice for your household, please contact our Corporate Secretary at Grace Therapeutics, Inc., 103 Carnegie Center, Suite 300, Princeton, New Jersey, or via telephone at (609)-322-1602. If you participate in householding and wish to receive a separate copy of the Notice, or if you do not wish to continue to participate in householding and prefer to receive separate copies of the Notice in the future, please contact our Corporate Secretary as indicated above.

If your shares are held in street name through a broker, bank or other nominee, please contact your broker, bank or nominee directly if you have questions, require additional copies of our materials or wish to receive a single copy of such materials in the future for all beneficial owners of shares of our common stock sharing an address.

Your vote is important. Even if you plan to attend the Annual Meeting, we urge you to submit your proxy or voting instructions as soon as possible.

Princeton, New Jersey

July 28, 2026

A copy of the Company’s Annual Report to the SEC on Form 10-K for the fiscal year ended March 31, 2026 is available without charge upon written request to: Corporate Secretary, Grace Therapeutics, Inc., 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.

The Company is a reporting issuer under the securities laws of certain provinces of Canada, with the Autorité des marchés financiers as its principal regulator. In reliance on exemptions available to SEC foreign issuers under Canadian securities legislation, including National Instrument 71-102 – Continuous Disclosure and Other Exemptions Relating to Foreign Issuers, the Company is furnishing this Proxy Statement, prepared in accordance with U.S. securities laws, to satisfy its proxy solicitation and continuous disclosure obligations under applicable Canadian securities laws. This Proxy Statement and accompanying materials will be filed with the applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca.